BRISTOL-MYERS SQUIBB COMPANY Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax of $26.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2026-06-30 was $26.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2026-03-31 was $39.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2025-06-30 was -$181.00M, a 351.39% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2025-03-31 was -$154.00M, a 174.40% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2025 was -$267.00M, a 165.28% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2024 was $409.00M, a 605.17% increase from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2023 was $58.00M, a 88.54% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2022 was $506.00M, a 53.33% increase from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $26.00M 10-Q · filed 2026-07-30 | $65.00M 10-Q · filed 2026-07-30 | ||
| 2026-03-31 | $39.00M 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | -$267.00M 10-K · filed 2026-02-11 | |||
| 2025-06-30 | -$181.00M 10-Q · filed 2026-07-30 | -$335.00M 10-Q · filed 2026-07-30 | -$72.00M derived: sum of 3 quarters · filed 2026-07-30 | -$205.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$154.00M 10-Q · filed 2026-04-30 | $109.00M derived: sum of 2 quarters · filed 2026-04-30 | -$24.00M derived: sum of 3 quarters · filed 2026-04-30 | $48.00M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $263.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $130.00M derived: sum of 2 quarters · filed 2026-02-11 | $202.00M derived: sum of 3 quarters · filed 2026-02-11 | $409.00M 10-K · filed 2026-02-11 |
| 2024-09-30 | -$133.00M 10-Q · filed 2024-10-31 | -$61.00M derived: sum of 2 quarters · filed 2024-10-31 | $146.00M 10-Q · filed 2024-10-31 | $4.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $72.00M 10-Q · filed 2024-07-26 | $279.00M 10-Q · filed 2024-07-26 | $137.00M derived: sum of 3 quarters · filed 2026-02-11 | $269.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $207.00M 10-Q · filed 2025-04-24 | $65.00M derived: sum of 2 quarters · filed 2026-02-11 | $197.00M derived: sum of 3 quarters · filed 2026-02-11 | $275.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | -$142.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$10.00M derived: sum of 2 quarters · filed 2026-02-11 | $68.00M derived: sum of 3 quarters · filed 2026-02-11 | $58.00M 10-K · filed 2026-02-11 |
| 2023-09-30 | $132.00M 10-Q · filed 2024-10-31 | $210.00M derived: sum of 2 quarters · filed 2024-10-31 | $200.00M 10-Q · filed 2024-10-31 | -$253.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $78.00M 10-Q · filed 2024-07-26 | $68.00M 10-Q · filed 2024-07-26 | -$385.00M derived: sum of 3 quarters · filed 2025-02-12 | $54.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | -$10.00M 10-Q · filed 2024-04-25 | -$463.00M derived: sum of 2 quarters · filed 2025-02-12 | -$24.00M derived: sum of 3 quarters · filed 2025-02-12 | $392.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | -$453.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$14.00M derived: sum of 2 quarters · filed 2025-02-12 | $402.00M derived: sum of 3 quarters · filed 2025-02-12 | $506.00M 10-K · filed 2025-02-12 |
| 2022-09-30 | $439.00M 10-Q · filed 2023-10-26 | $855.00M derived: sum of 2 quarters · filed 2023-10-26 | $959.00M 10-Q · filed 2023-10-26 | $1.00B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $416.00M 10-Q · filed 2023-07-27 | $520.00M 10-Q · filed 2023-07-27 | $563.00M derived: sum of 3 quarters · filed 2024-02-13 | $643.00M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $104.00M 10-Q · filed 2023-04-27 | $147.00M derived: sum of 2 quarters · filed 2024-02-13 | $227.00M derived: sum of 3 quarters · filed 2024-02-13 | $186.00M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $43.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $123.00M derived: sum of 2 quarters · filed 2024-02-13 | $82.00M derived: sum of 3 quarters · filed 2024-02-13 | $330.00M 10-K · filed 2024-02-13 |
| 2021-09-30 | $80.00M 10-Q · filed 2022-10-26 | $39.00M derived: sum of 2 quarters · filed 2022-10-26 | $287.00M 10-Q · filed 2022-10-26 | $139.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | -$41.00M 10-Q · filed 2022-07-27 | $207.00M 10-Q · filed 2022-07-27 | $59.00M derived: sum of 3 quarters · filed 2023-02-14 | -$59.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $248.00M 10-Q · filed 2022-04-29 | $100.00M derived: sum of 2 quarters · filed 2023-02-14 | -$18.00M derived: sum of 3 quarters · filed 2023-02-14 | -$48.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | -$148.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | -$266.00M derived: sum of 2 quarters · filed 2023-02-14 | -$296.00M derived: sum of 3 quarters · filed 2023-02-14 | -$209.00M 10-K · filed 2023-02-14 |
| 2020-09-30 | -$118.00M 10-Q · filed 2021-10-27 | -$148.00M derived: sum of 2 quarters · filed 2021-10-27 | -$61.00M 10-Q · filed 2021-10-27 | -$93.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-06-30 | -$30.00M 10-Q · filed 2021-07-28 | $57.00M 10-Q · filed 2021-07-28 | $25.00M derived: sum of 3 quarters · filed 2022-02-09 | $80.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-03-31 | $87.00M 10-Q · filed 2021-04-29 | $55.00M derived: sum of 2 quarters · filed 2022-02-09 | $110.00M derived: sum of 3 quarters · filed 2022-02-09 | $105.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2019-12-31 | -$32.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $23.00M derived: sum of 2 quarters · filed 2022-02-09 | $18.00M derived: sum of 3 quarters · filed 2022-02-09 | $58.00M 10-K · filed 2022-02-09 |
| 2019-09-30 | $55.00M 10-Q · filed 2020-11-05 | $50.00M derived: sum of 2 quarters · filed 2020-11-05 | $90.00M 10-Q · filed 2020-11-05 | $110.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-06-30 | -$5.00M 10-Q · filed 2020-08-06 | $35.00M 10-Q · filed 2020-08-06 | $55.00M derived: sum of 3 quarters · filed 2021-02-10 | $71.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-03-31 | $40.00M 10-Q · filed 2020-05-07 | $60.00M derived: sum of 2 quarters · filed 2021-02-10 | $76.00M derived: sum of 3 quarters · filed 2021-02-10 | $149.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2018-12-31 | $20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | $36.00M derived: sum of 2 quarters · filed 2021-02-10 | $109.00M derived: sum of 3 quarters · filed 2021-02-10 | $77.00M 10-K · filed 2021-02-10 |
| 2018-09-30 | $16.00M 10-Q · filed 2019-10-31 | $89.00M derived: sum of 2 quarters · filed 2019-10-31 | $57.00M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $73.00M 10-Q · filed 2019-07-25 | $41.00M 10-Q · filed 2019-07-25 | ||
| 2018-03-31 | -$32.00M 10-Q · filed 2019-04-25 | |||
| 2017-12-31 | -$68.00M 10-K · filed 2020-02-24 | |||
| 2016-12-31 | -$5.00M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |